Physician profile
David Johnson
NPI 1386616795
$8,978.41
in general payments reported to CMS, 2019-2025
64 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,096 · 2020: $770 · 2021: $1,421 · 2022: $970 · 2023: $1,722 · 2024: $1,688 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,706 · Education: $15.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,706.40 |
| Education | $15.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $971.22 | 2019-2025 | |
| Abbvie INC. | $950.59 | 2019-2025 | |
| Amgen INC. | $752.31 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $683.49 | 2022-2024 | Eterna, Proclaim, Freestyle Libre 3 |
| Lilly USA, LLC | $579.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $383.32 | 2019-2025 | Rybelsus, Ozempic, Saxenda |
| Astrazeneca Pharmaceuticals LP | $376.16 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $280.24 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astellas Pharma US INC | $275.28 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $254.78 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.57 | 2019-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.95 | 2019-2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $182.67 | 2023-2025 | Gemtesa |
| Supernus Pharmaceuticals, INC. | $175.17 | 2019 | Tlando, Xyosted |
| Teva Pharmaceuticals USA, INC. | $171.14 | 2019-2024 | Austedo Xr |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $157.52 | 2023-2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $153.05 | 2021 | |
| Spr Therapeutics, INC | $152.83 | 2019 | |
| Antares Pharma, INC. | $149.72 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Phathom Pharmaceuticals, INC. | $132.05 | 2024-2025 | Voquezna |
| Allergan, INC. | $113.01 | 2020 | |
| Vanda Pharmaceuticals INC. | $91.47 | 2024-2025 | Fanapt, Hetlioz |
| Bard Peripheral Vascular, INC. | $84.28 | 2021 | |
| Novartis Pharmaceuticals Corporation | $83.47 | 2021 | |
| Exact Sciences Corporation | $79.19 | 2023-2025 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $77.99 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $75.91 | 2022-2024 | Zoryve, Livalo, Seglentis |
| Axsome Therapeutics, INC. | $74.71 | 2025 | Sunosi, Auvelity |
| Daiichi Sankyo INC. | $65.36 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $58.47 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.88 | 2022 | |
| Cerapedics INC. | $53.38 | 2025 | I-Factor Peptide Enhanced Bone Graft |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.18 | 2024-2025 | Caplyta |
| Medtronic, INC. | $48.92 | 2022-2025 | Inceptiv, Closurefast |
| Dexcom, INC. | $48.28 | 2021-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $47.73 | 2022-2023 | |
| Corcept Therapeutics | $44.13 | 2025 | Korlym |
| Amarin Pharma, INC. | $39.80 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $33.87 | 2019-2023 | Xarelto |
| Mycovia Pharmaceuticals, INC. | $33.22 | 2023 | Vivjoa |
| Hikma Pharmaceuticals USA | $31.41 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $30.37 | 2020 | |
| Noven Therapeutics, LLC | $29.78 | 2024 | Xelstrym |
| Endo Pharmaceuticals INC. | $29.59 | 2019-2022 | |
| Ibsa Pharma INC. | $28.70 | 2020-2023 | Tirosint, Licart |
| E.R. Squibb & Sons, L.L.C. | $24.71 | 2024 | Eliquis |
| Genentech USA, INC. | $24.62 | 2020 | |
| Aytu Biopharma, INC. | $23.42 | 2019 | |
| Heron Therapeutics, INC. | $20.96 | 2021 | |
| Halozyme INC | $20.42 | 2023 | |
| Abiomed | $20.10 | 2023 | Impella |
| Sanofi Pasteur INC. | $20.07 | 2023 | |
| Esperion Therapeutics, INC. | $19.11 | 2020 | |
| Phadia US INC. | $19.08 | 2019 | |
| Horizon Therapeutics Plc | $17.83 | 2023 | Krystexxa |
| Shire North American Group INC | $17.55 | 2019 | |
| Almatica Pharma LLC | $17.17 | 2022 | |
| Cranial Technologies, INC | $16.85 | 2025 | Doc Band |
| Curonix LLC | $15.58 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Gilead Sciences, INC. | $15.50 | 2020 | |
| Irhythm Technologies, INC. | $14.64 | 2024 | Zio Monitor, Zio Xt Patch |
| Eisai INC. | $14.56 | 2020 | |
| Bardy Diagnostics, INC. | $13.00 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.88 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.